Opinion|Videos|March 28, 2025
Tailoring Immunotherapy Strategies for the Advanced NSCLC
Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.
Advertisement
Video content above is prompted by the following:
- How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
- In which patients do you consider the addition of chemotherapy?
- How does PD-L1 status influence your decision?
- What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
- What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
- What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?
Advertisement
Related to this article
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
FDA Flashback: Breast Cancer Decisions and News From June 2026
3
Interpreting Efficacy Data and Assessing Risk-Benefit in a Curative-Intent Population
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5